106 related articles for article (PubMed ID: 18327815)
1. Editorial. Endometrioid epithelial ovarian cancer.
Cibull ML; Karabakhtsian RG
Cancer; 2008 May; 112(10):2108-11. PubMed ID: 18327815
[No Abstract] [Full Text] [Related]
2. Endometrioid epithelial ovarian cancer : 20 years of prospectively collected data from a single center.
Storey DJ; Rush R; Stewart M; Rye T; Al-Nafussi A; Williams AR; Smyth JF; Gabra H
Cancer; 2008 May; 112(10):2211-20. PubMed ID: 18344211
[TBL] [Abstract][Full Text] [Related]
3. A randomized comparison of triptorelin and tamoxifen as treatment of progressive ovarian cancer.
Jager W; Sauerbrei W; Beck E; Maassen V; Stumpfe M; Meier W; Kuhn W; Janicke F
Anticancer Res; 1995; 15(6B):2639-42. PubMed ID: 8669839
[No Abstract] [Full Text] [Related]
4. A phase II clinical trial of topotecan in Japanese patients with relapsed ovarian carcinoma.
Aoki D; Katsumata N; Nakanishi T; Kigawa J; Fujiwara K; Takehara K; Kamiura S; Hiura M; Hatae M; Sugiyama T; Ochiai K; Noda K
Jpn J Clin Oncol; 2011 Mar; 41(3):320-7. PubMed ID: 20974678
[TBL] [Abstract][Full Text] [Related]
5. [Factors of resistance of ovarian cancer to combined chemotherapy with the use of platinum derivatives].
Bliumenberg AG; Gorbacheva LB; Gorbunova VA; Kozachenko VP; Lankin VZ
Biull Eksp Biol Med; 1996 Dec; 122(12):651-4. PubMed ID: 9280465
[No Abstract] [Full Text] [Related]
6. Phase II clinical study on the GEMOX regimen as second- line therapy for advanced ovarian cancer.
Yuan SF; Zhang LP; Zhu LJ; Chen WJ; Zheng WE; Xiong JP
Asian Pac J Cancer Prev; 2013; 14(6):3949-53. PubMed ID: 23886213
[TBL] [Abstract][Full Text] [Related]
7. The impact of race on survival in uterine serous carcinoma: a hospital-based study.
Al-Wahab Z; Ali-Fehmi R; Cote ML; Elshaikh MA; Ibrahim DR; Semaan A; Schultz D; Morris RT; Munkarah AR
Gynecol Oncol; 2011 Jun; 121(3):577-80. PubMed ID: 21377196
[TBL] [Abstract][Full Text] [Related]
8. Prognostic factors for high-risk early-stage epithelial ovarian cancer: a Gynecologic Oncology Group study.
Chan JK; Tian C; Monk BJ; Herzog T; Kapp DS; Bell J; Young RC;
Cancer; 2008 May; 112(10):2202-10. PubMed ID: 18348296
[TBL] [Abstract][Full Text] [Related]
9. WT-1 in ovarian and endometrioid serous carcinoma: a meta-analysis.
Heatley MK
Histopathology; 2005 Apr; 46(4):468. PubMed ID: 15810962
[No Abstract] [Full Text] [Related]
10. Haematological evaluation of weekly therapy with topotecan for the treatment of recurrent ovarian cancer resistant to platinum-based therapy.
Largillier R; Valenza B; Ferrero JM; Novo C; Creisson A; Lesbats G; Mari V; Hebert C; Chamorey E
Oncology; 2007; 73(3-4):177-84. PubMed ID: 18418010
[TBL] [Abstract][Full Text] [Related]
11. Simultaneous endometrial malignant mixed mesodermal tumor and ovarian serous adenocarcinoma.
Krigman HR; Coogan AC; Marks JR
Arch Pathol Lab Med; 1995 Jan; 119(1):99-103. PubMed ID: 7802567
[TBL] [Abstract][Full Text] [Related]
12. Pegylated liposomal doxorubicin in heavily pretreated epithelial ovarian cancer patients.
Gorumlu G; Kucukzeybek Y; Kemal-Gul M; Karaca B; Cosan-Terek M; Karabulut B; Sanli UA; Akman L; Ozsaran A; Dikmen Y; Uslu R
J BUON; 2008; 13(3):349-52. PubMed ID: 18979548
[TBL] [Abstract][Full Text] [Related]
13. Systematic pelvic lymphadenectomy vs. no lymphadenectomy in early-stage endometrial carcinoma: randomized clinical trial.
Benedetti Panici P; Basile S; Maneschi F; Alberto Lissoni A; Signorelli M; Scambia G; Angioli R; Tateo S; Mangili G; Katsaros D; Garozzo G; Campagnutta E; Donadello N; Greggi S; Melpignano M; Raspagliesi F; Ragni N; Cormio G; Grassi R; Franchi M; Giannarelli D; Fossati R; Torri V; Amoroso M; Crocè C; Mangioni C
J Natl Cancer Inst; 2008 Dec; 100(23):1707-16. PubMed ID: 19033573
[TBL] [Abstract][Full Text] [Related]
14. Pegylated liposomal doxorubicin re-challenge in patients with ovarian cancer relapse: a multicenter retrospective study.
Tripodi E; Cormio G; De Giorgi U; Valabrega G; Rubino D; Lepori S; Maltese G; Sabatucci I; Lorusso D
Int J Gynecol Cancer; 2019 Jan; 29(1):153-157. PubMed ID: 30640698
[No Abstract] [Full Text] [Related]
15. [Five years survival in patients with endometrioid ovarian cancer versus patients with serous ovarian cancer].
Ivanov S; Batashki I
Akush Ginekol (Sofiia); 2008; 47(5):9-11. PubMed ID: 19227770
[TBL] [Abstract][Full Text] [Related]
16. Epidemiology of low-grade serous ovarian cancer.
Plaxe SC
Am J Obstet Gynecol; 2008 Apr; 198(4):459.e1-8; discussion 459.e8-9. PubMed ID: 18395040
[TBL] [Abstract][Full Text] [Related]
17. For women receiving chemotherapy for clinically apparent early ovarian cancer, is there a benefit to surgical staging?
Dizon DS; Restivo A; Lomme M; Charbonneau N; Brard L; Hughes T; Weitzen S; Legare R; Granai CO; Disilvestro P
Am J Clin Oncol; 2008 Feb; 31(1):39-42. PubMed ID: 18376226
[TBL] [Abstract][Full Text] [Related]
18. Stage IVB endometrial cancer: does applying an ovarian cancer treatment paradigm result in similar outcomes? A case-control analysis.
Landrum LM; Moore KN; Myers TK; Lanneau GS; McMeekin DS; Walker JL; Gold MA
Gynecol Oncol; 2009 Feb; 112(2):337-41. PubMed ID: 19041126
[TBL] [Abstract][Full Text] [Related]
19. Recurrent low-grade serous ovarian carcinoma is relatively chemoresistant.
Gershenson DM; Sun CC; Bodurka D; Coleman RL; Lu KH; Sood AK; Deavers M; Malpica AL; Kavanagh JJ
Gynecol Oncol; 2009 Jul; 114(1):48-52. PubMed ID: 19361839
[TBL] [Abstract][Full Text] [Related]
20. [Uterine papillary serous carcinoma--a different kind of tumor].
Steinman N; Avni A
Harefuah; 1999 May; 136(10):810-2. PubMed ID: 10955120
[No Abstract] [Full Text] [Related]
[Next] [New Search]
